VOL. 68, NO 9 | November 2019
Financial Support Provided by
Peer reviewed by The Journal of Family Practice

Management of the T2D Patient With High A1C

It is widely known that the extent of time spent in a state of hyperglycemia increases the risk of complications for patients with type 2 diabetes (T2D). However, despite the availability of many antihyperglycemic agents, success in managing T2D has not dramatically improved in recent years. Indeed, therapeutic inertia – the failure to initiate or intensify treatment – is a well-characterized phenomenon. In this roundtable, the speakers discuss the management of individuals with A1C  ≥9% despite treatment with 2 or 3 oral antihyperglycemic agents, who represent a large patient population requiring treatment intensification.

This peer-reviewed publication was developed in adherence with Good Publication Practice (GPP3) guidelines. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have disclosed all potential conflicts of interest.


Click here for the speakers' disclosures

Severity of complications emanating from lack of glycemic control
Implications of beta-cell preservation in treatment outcomes
Therapeutic approaches in patients with inadequately controlled T2D
Timely treatment intensification for optimal glycemic control of T2D
Counseling Patients

Video not playing? Download Flash Player here

Part 1: Introduction to real-world evidence


Click here or on the thumbnail above to read the abstract for this video roundtable discussion.

Click here for the speakers' disclosures

About the Panel

Juan P. Frias, MD

Juan P. Frias, MD, FACE

  • Endocrinologist
  • National Research Institute
  • Los Angeles, CA
Eugene Wright, MD

Eugene Wright, MD

  • Consulting Associate
  • Duke Southern Regional AHEC
  • Fayetteville, NC
Jodi Strong, DNP

Katherine Whitmire, NP-c, CDE, BC-ADM

  • Nurse Practitioner
  • Southwest Medical Associates
  • Las Vegas, NV


  • Dr. Frias has received research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson and Johnson, Merck, Novo Nordisk, Pfizer, Sanofi, and Theracos. He is on the advisory boards and is a consultant for Boehringer Ingelheim, Eli Lilly, Johnson and Johnson, Merck, Novo Nordisk, and Sanofi. He is on the speakers’ bureaus for Merck and Sanofi.
  • Dr. Wright is on the advisory board for Abbott Diabetes Care. He is an advisor and consultant for Abbott Diabetes Care, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim/Lilly, Merck, Sanofi, and Voluntis. He is a speaker for Abbott Diabetes Care, Boehringer Ingelheim, and Boehringer Ingelheim/Lilly.
  • Ms. Whitmire has no conflicts of interest to disclose.


  • This roundtable was funded by Sanofi US, Inc. The authors received writing editorial support in the preparation of the material provided by Helen Jones, PhD, CMPP, of Evidence Scientific Solutions, funded by Sanofi US, Inc.